Nov 18, 2020 20:11 JST

Source: Eisai

Eisai Selected for Membership in Dow Jones Sustainability Asia Pacific Index 2020 for Seventh Time


TOKYO, Nov 18, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been selected for a membership in the Dow Jones Sustainability Asia Pacific Index (DJSI Asia Pacific), the Asia Pacific version of the Dow Jones Sustainability Indices (DJSI), which are a family of premier global indices for socially responsible investment (SRI). This marks Eisai?s seventh selection.

The DJSI family was jointly established between RobecoSAM AG (Switzerland) and S&P Dow Jones Indices LLC (United States) in 1999 and assesses the corporate sustainability performance of eligible member companies based on economic, environmental and social criteria. The DJSI is one of the important investment criteria for the investors around the world who emphasize on corporate initiatives for improving non-financial value focused on environmental, social, and governance (ESG).This year, the DJSI Asia Pacific has selected top 158 companies (82 of which are from Japan) from among the approximate major 600 companies in the region. Eisai received high scores in categories such as Innovation Management, Climate Strategy, Environmental Reporting as well as Human Rights.

In addition to the DJSI Asia Pacific, Eisai has been selected for the FTSE4Good Index Series, which is another global benchmark SRI index as well as for the MSCI Japan Empowering Women Index (WIN), the FTSE Blossom Japan Index, the MSCI Japan ESG Select Leaders Index and S&P/JPX Carbon Efficient Index, which are the four ESG investment indices for Japanese stocks adopted by the Government Pension Investment Fund (GPIF).

Eisai?s corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. By strengthening its ESG initiatives and increasing non-financial value, Eisai is striving to sustainably enhance corporate value based on this corporate philosophy.

Contact:
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: Healthcare & Pharm

Copyright ©2021 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


New Drug Approval for in-House Developed Anti-Insomnia Drug Dayvigo (Lemborexant) in Hong Kong
March 02 2021 08:06 JST
 
Eisai: MHLW Grants Orphan Drug Designation in Japan to Novel FGF Receptor Selective Tyrosine Kinase Inhibitor E7090
February 22 2021 14:40 JST
 
Eisai Receives Corporate Philanthropy Award for Its Efforts to Realize Human Health Care (hhc) Philosophy
February 22 2021 12:11 JST
 
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrated Superior Progression-Free Survival (PFS) and Overall Survival (OS) Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
February 15 2021 10:07 JST
 
Eisai to Launch Parkinson's Disease Treatment Equfina in South Korea
February 01 2021 08:35 JST
 
Eisai Listed as a Global 100 Most Sustainable Corporation for the Fifth Time
January 26 2021 10:58 JST
 
Eisai to Present Abstracts on Lenvatinib at 2021 Gastrointestinal Cancers Symposium
January 12 2021 11:37 JST
 
Eisai Completes Construction of the 5th Manufacturing Building at Kawashima Industrial Park in Japan
December 18 2020 12:09 JST
 
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Demonstrated Statistically Significant Improvement in OS, PFS and ORR
December 17 2020 11:47 JST
 
Eisai: Biogen Files New Drug Application for Aducanumab in Japan
December 11 2020 09:43 JST
 
More Press release >>

Latest Press Release


More Latest Release >>